Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

As global markets navigate a muted response to new U.S. tariffs and mixed economic signals, the Asian tech sector remains a focal point for investors seeking high growth opportunities. With market ...

Stocks like Wipro, Axis Bank, LTIMindtree, Indian Hotels, Lupin, Tracxn Technologies, Capital Small Finance Bank, Veranda ...

On May 6, Arcutis reported first-quarter results showed loss of 20 cents a share, which slightly beat estimates. Its sales ...

The U.S. stock market has been navigating a wave of uncertainty, with recent tariff threats from President Trump causing fluctuations across major indices such as the Dow Jones, S&P 500, and Nasdaq.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

National Bank Financial analyst Maxim Sytchev, who has an “outperform” rating and $28 target, said he expects the sale of the ...

Their first product, Illuccix, is a diagnostic imaging agent that allows PET scanners to light up the prostate cancer cells ...

Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering.

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.